Vivos Therapeutics, Inc.
VVOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $6,783 | $3,820 | $3,016 | $3,698 |
| % Growth | 77.6% | 26.7% | -18.4% | – |
| Cost of Goods Sold | $2,846 | $1,710 | $1,507 | $1,601 |
| Gross Profit | $3,937 | $2,110 | $1,509 | $2,097 |
| % Margin | 58% | 55.2% | 50% | 56.7% |
| R&D Expenses | $0 | $0 | $0 | $100 |
| G&A Expenses | $7,884 | $6,409 | $4,892 | $4,347 |
| SG&A Expenses | $8,287 | $6,669 | $5,250 | $4,759 |
| Sales & Mktg Exp. | $403 | $260 | $358 | $412 |
| Other Operating Expenses | $0 | $0 | $0 | $44 |
| Operating Expenses | $8,287 | $6,669 | $5,250 | $4,903 |
| Operating Income | -$4,350 | -$4,865 | -$3,741 | -$2,806 |
| % Margin | -64.1% | -127.4% | -124% | -75.9% |
| Other Income/Exp. Net | -$1,050 | -$454 | $54 | -$21 |
| Pre-Tax Income | -$5,400 | -$5,013 | -$3,864 | -$2,827 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,400 | -$5,013 | -$3,864 | -$2,827 |
| % Margin | -79.6% | -131.2% | -128.1% | -76.4% |
| EPS | -0.49 | -0.55 | -0.45 | -0.48 |
| % Growth | 10.9% | -22.2% | 6.2% | – |
| EPS Diluted | -0.49 | -0.55 | -0.45 | -0.48 |
| Weighted Avg Shares Out | 10,964 | 9,087 | 8,595 | 5,890 |
| Weighted Avg Shares Out Dil | 10,964 | 9,087 | 8,595 | 5,890 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $384 | $306 | $177 | $144 |
| EBITDA | -$5,016 | -$4,707 | -$3,564 | -$2,683 |
| % Margin | -73.9% | -123.2% | -118.2% | -72.6% |